Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

Cancer Research

Volumn 57, Issue 2, 1997, Pages 314-319

  Koivisto, Pasi ^a,b   Kononen, Juha ^a,b   Palmberg, Christian ^b   Tammela, Teuvo ^b   Hyytinen, Eija ^a,b   Isola, Jorma ^a,b   Trapman, Jan ^c   Cleutjens, Kitty ^c   Noordzij, Arjan ^c   Visakorpi, Tapio ^a,b,d   Kallioniemi, Olli P ^a,b,d  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; GONADORELIN DERIVATIVE; MESSENGER RNA;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT FAILURE;

AGED; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 15644368237     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Potosky, A. L., Miller, B. A., Albertsen, P. C., and Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc., 273: 548-552, 1995.
2. Gittes, R. F. Carcinoma of the prostate. N. Engl. J. Med., 324: 236-245, 1991.
3. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 6319-6323, 1992.
4. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S., and Shimazaki, J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759-765, 1993.
5. Culig, Z., Hobisch, A., Cronauer, M., V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
6. Gaddipati, J. P., McLeod, D. G., Heidenberg, H. B., Sesterhenn, I. A., Finger, M. J., Moul, J. W., and Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res., 54: 2861-2864, 1994.
7. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H., and van der Kwast, T. H. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol., 144: 735-746, 1994.
8. 24 → 18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun., 198: 74-80, 1994.
9. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
10. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
11. Alt, F. W., Kellems, R. E., Bertino, J. R., and Schimke, R. T. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem., 253: 1357-1370, 1978.
12. Kellens, R. E. Gene Amplification in Mammalian Cells. A comprehensive guide. New York: Marcel Dekker Inc., 1993.
13. Kallioniemi, O-P., and Visakorpi, T. Genetic basis and clonal evolution of human prostate cancer. Adv. Cancer Res., 68: 225-255, 1996.
14. Murphy, G. P., Slack, N. H., and Mittelman, A. Use of estramustine phosphate by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology, 23 (Suppl. 6): 54-63, 1984.
15. Hyytinen, E., Visakorpi, T., Kallioniemi, A., Kallioniemi, O-P., and Isola, J. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry, 16: 93-99, 1994.
16. Kononen, J., Paavola, M., Penttilä, T-L., Parvinen, M., and Pelto-Huikko, M. Stage- specific expression of pituitary adenylate cyclase activating polypeptide (PACAP) mRNA in the rat seminiferous tubules. Endocrinology, 135: 2291-2294, 1994.
17. Govindan, M. V. Specific region in hormone binding domain is essential for hormone binding and trans-activation by human androgen receptor. Mol. Endocrinol., 4: 417-427, 1990.
18. Ris-Stalpers, C., Trifiro, M. A., Kuiper, G. G. J. M., Jenster, G., Romalo, G., Sai T., van Rooij, H. C. J., Kaufman, M., Rosenfield, R. L., Liao, S., Schweikert, H.-U., Trapman, J., Pinsky, L., and Brinkmann, A. O. Substitution of aspartatic acid 686 by histidine or aspargine in the human androgen receptor leads to functionally inactive androgen receptors with altered hormone binding characteristics. Mol. Endocrinol., 5: 1562-1569, 1991.
19. Brinkmann, A. O., Faber, P. W., van Rooij, H. C. J., Kuiper, G. G. J. M., Ris, C., Klaassen, J. A. G. M., van der Korput, J. A. G. M., Voorhorst, M. M., van Laar, J. H., Mulder, E., and Trapman, J. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem., 34: 307-310, 1989.
20. Cleutjens, K. B. J. M., van Eekelen, C. C. E. M., van der Korput, H. A. G. M., Brinkman, A. O., and Trapman, J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate specific antigen promoter. J. Biol. Chem., 271: 6379-6388, 1996,
21. Dixon, W. J. BMDP Statistical Software. Berkeley: University of California Press, 1981.
22. Van der Kwast, T. H., Schalken, J. Ruizeeld de Winter, J. A., van Vroonhoven, C. C. J., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
23. Göker, E., Waltham, M., Kheradpour, A., Trippelt, T., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P., Tan, C., Berman, E., and Bertino, J. R. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoplastic leukemia and is correlated with p53 gene mutations. Blood, 86: 677-684, 1995.
24. Hamlin, J. L., Leu, T-H., Vaughn, J. P., Ma, C., and Dijkwell, P. A. Amplification of DNA sequences in mammalian cells. Prog. Nucleic Acid Res., 41: 203-239, 1991.
25. Wahl, G. M. The importance of circular DNA in mammalian gene amplification. Cancer Res., 49: 1333-1340, 1989.
26. Wright, J. A., Smith, H. S., Watt, F. M., Hancock, M. C., Hudson, D. L., and Stark, G. R. DNA amplification is rare in normal human cells. Proc. Natl. Acad. Sci. USA, 87: 1791-1795, 1990.
27. Tlsty, T. D., White, A., and Sanchez, J. Suppression of gene amplification in human cell hybrids. Science (Washington DC), 255: 1425-1427, 1992.
28. Stark, G. R. Regulation and mechanisms of mammalian gene amplification. Adv. Cancer. Res., 61: 87-113, 1993.
29. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E.., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
30. Brison, O. Gene amplification and tumor progression. Biochim. Biophys. Acta, 1155: 25-41, 1993.
31. Logothetis, C. J., Hoosein, N. M., and Hsieh, J. T. The clinical and biological study of androgen independent prostate cancer (AI Pca). Semin. Oncol., 21: 620-629, 1994.
32. Labrie, F., Belanger, A., Dupont, A., Luu-The, V., Simard, J., and Labrie, C. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492, 1993.
33. Palmberg, C., Koivisto, P., Hyytinen, E., Isola, J., Visakorpi, T., Kallioniemi, O-P., and Tammela, T. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with nonsteroidal pure antiandrogen "Casodex" and favorable response to maximal androgen blockade. Eur. Urol., in press, 1996.
34. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
35. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet, 346: 265-269, 1995.